Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Profusa (PFSA) EPS (Weighted Average and Diluted) (2022 - 2026)

Profusa posted quarterly EPS (Weighted Average and Diluted) of -$2.05 for Q1 2026, up 98.05% year-on-year from -$1.04 in Q1 2025, and down 102.3% on a QoQ basis from $89.25 in Q4 2025.

Profusa (PFSA) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$2.05 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 98.05% year-over-year to -$2.05; the trailing twelve-month figure through Mar 2026 stood at $24.0 (up 105.22% YoY), and the FY2025 full-year result was -$107.01, up 70.04% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.05, down from $89.25 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $89.25 in Q4 2025 and bottomed at -$353.54 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.07 (2024), against an average of -$25.63.
  • The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) sank 883950.0%; it then surged 125.24% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.71 in 2022, then soared by 105.6% to $0.04 in 2023, then plunged by 883950.0% to -$353.54 in 2024, then soared by 125.24% to $89.25 in 2025, then slumped by 102.3% to -$2.05 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$2.05 (Q1 2026), $89.25 (Q4 2025), and -$61.67 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.61
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.93
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.89
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.90
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.66
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.51
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.85
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 2.24
10 Profusa 574,294.01 574,294.01 - -2.05

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -2.05
Dec 31, 2025 64.69
Sep 30, 2025 -52.45
Jun 30, 2025 -1.53
Mar 31, 2025 -0.19
Dec 31, 2024 -353.54
Sep 30, 2024 -1.29
Jun 30, 2024 -0.07
Mar 31, 2024 -0.14
Dec 31, 2023 0.04
Sep 30, 2023 -0.06
Jun 30, 2023 0.14
Mar 31, 2023 0.02
Dec 31, 2022 0.02
Sep 30, 2022 0.07
Jun 30, 2022 0.05
Mar 31, 2022 0.15